10/584952

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	595	(544/250,514/267).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/08/02 16:55
L2	34	l1 and triaza	US-PGPUB; USPAT	OR	ON	2007/08/02 16:55
L3	3	l2 and cyclopenta	US-PGPUB; USPAT	OR	ON	2007/08/02 16:56
L4	1	l3 and indene	US-PGPUB; USPAT	OR	ON	2007/08/02 16:56
L5	0	l4 and cd	US-PGPUB; USPAT	OR	ON	2007/08/02 16:56

~~10/513699~~ 10/584,952

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 15  WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS  3  MAR 16  CASREACT coverage extended
 NEWS  4  MAR 20  MARPAT now updated daily
 NEWS  5  MAR 22  LWPI reloaded
 NEWS  6  MAR 30  RDISCLOSURE reloaded with enhancements
 NEWS  7  APR 02  JICST-EPLUS removed from database clusters and STN
 NEWS  8  APR 30  GENBANK reloaded and enhanced with Genome Project ID field
 NEWS  9  APR 30  CHEMCATS enhanced with 1.2 million new records
 NEWS 10  APR 30  CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 11  APR 30  INPADOC replaced by INPADOCDB on STN
 NEWS 12  MAY 01  New CAS web site launched
 NEWS 13  MAY 08  CA/CAplus Indian patent publication number format defined
 NEWS 14  MAY 14  RDISCLOSURE on STN Easy enhanced with new search and display
                  fields
 NEWS 15  MAY 21  BIOSIS reloaded and enhanced with archival data
 NEWS 16  MAY 21  TOXCENTER enhanced with BIOSIS reload
 NEWS 17  MAY 21  CA/CAplus enhanced with additional kind codes for German
                  patents
 NEWS 18  MAY 22  CA/CAplus enhanced with IPC reclassification in Japanese
                  patents
 NEWS 19  JUN 27  CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 20  JUN 29  STN Viewer now available
 NEWS 21  JUN 29  STN Express, Version 8.2, now available
 NEWS 22  JUL 02  LEMBASE coverage updated
 NEWS 23  JUL 02  LMEDLINE coverage updated
 NEWS 24  JUL 02  SCISEARCH enhanced with complete author names
 NEWS 25  JUL 02  CHEMCATS accession numbers revised
 NEWS 26  JUL 02  CA/CAplus enhanced with utility model patents from China
 NEWS 27  JUL 16  CAplus enhanced with French and German abstracts
 NEWS 28  JUL 18  CA/CAplus patent coverage enhanced
 NEWS 29  JUL 26  USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS 30  JUL 30  USGENE now available on STN

 NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:35:20 ON 02 AUG 2007

```
=> file reg
COST IN U.S. DOLLARS                            SINCE FILE       TOTAL
                                                   ENTRY     SESSION
FULL ESTIMATED COST                                 0.84        0.84

FILE 'REGISTRY' ENTERED AT 10:37:42 ON 02 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 AUG 2007  HIGHEST RN 943895-11-2
DICTIONARY FILE UPDATES:   1 AUG 2007  HIGHEST RN 943895-11-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10584952.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 H,Cb,Ak,OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,O,CN

G2 H,X,Cb,Ak,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,O,S,N

G3 C,H,Cb,Ak

G4 C,H,O,Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 10:38:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        8 TO ITERATE

100.0% PROCESSED        8 ITERATIONS                              3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          8 TO      329
PROJECTED ANSWERS:             3 TO      163

L2            3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:38:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      200 TO ITERATE

100.0% PROCESSED      200 ITERATIONS                             42 ANSWERS
SEARCH TIME: 00.00.01

L3           42 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             172.10     172.94

FILE 'CAPLUS' ENTERED AT 10:38:23 ON 02 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Aug 2007  VOL 147 ISS 6
FILE LAST UPDATED: 1 Aug 2007  (20070801/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4            1 L3

=> d ibib abs hitstr tot

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2005:638885  CAPLUS
DOCUMENT NUMBER:          143:153394
TITLE:                    Preparation of triaza-cyclopenta[cd]indene derivatives
                          as CRF antagonists
INVENTOR(S):              Nakazato, Atsuro; Okubo, Taketoshi; Nozawa, Dai;
                          Tamita, Tomoko; Kennis, Ludo E. J.
PATENT ASSIGNEE(S):       Taisho Pharmaceutical Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 23 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     WO 2005066178        A1    20050721    WO 2005-JP323          20050106
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW:  BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     CA 2552600           A1    20050721    CA 2005-2552600        20050106
     EP 1704149           A1    20060927    EP 2005-703562         20050106
     EP 1704149           B1    20070307
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
             BA, HR, IS, YU
```

CN 1910187	A	20070207	CN 2005-80002037		20050106
AT 356129	T	20070315	AT 2005-703562		20050106
JP 2007517795	T	20070705	JP 2006-546615		20050106
US 2007060602	A1	20070315	US 2006-584952		20060913
PRIORITY APPLN. INFO.:			JP 2004-1312	A	20040106
			WO 2005-JP323	W	20050106

OTHER SOURCE(S): CASREACT 143:153394; MARPAT 143:153394

GI



I



II

AB The title compds. I [R1, R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl, cycloalkyl, cycloalkylalkyl; R5 = H, alkyl, arylalkyl, carbamoyl; Ar = (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts] which have a high affinity for CRF receptors and are effective against diseases in which CRF is considered to be involved, were prepared E.g., a multi-step synthesis of II.HCl, starting from 8-(2-bromo-4-isopropylphenyl)-4-chloro-2-methylpyrrolo[1,2-a]pyrimidine-6-carbonitrile and 1-propylbutanamine, was given. Representative compds. I showed IC50 of ≤ 100 nM in CRF receptor binding test. An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, dermatitis, schizophrenia, pain, etc.

IT 860016-16-6P 860016-18-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triaza-cyclopenta[cd]indene derivs. as CRF antagonists)

RN 860016-16-6 CAPLUS

CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-18-8 CAPLUS

CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-[2-bromo-4-(1-methylethyl)phenyl]-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 860016-14-4P 860016-15-5P 860016-17-7P
860016-19-9P 860016-20-2P 860016-22-4P
860016-24-6P 860016-25-7P 860016-26-8P
860016-27-9P 860016-28-0P 860016-29-1P
860016-31-5P 860016-32-6P 860016-34-8P
860016-35-9P 860016-37-1P 860016-38-2P
860016-40-6P 860016-41-7P 860016-42-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triaza-cyclopenta[cd]indene derivs. as CRF antagonists)

RN 860016-14-4 CAPLUS

CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(2,4-dichlorophenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-15-5 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 6-methyl-1-(1-propylbutyl)-4-(2,4,6-trimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-17-7 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-chloro-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-19-9 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-[2-bromo-4-(trifluoromethyl)phenyl]-6-methyl-1-(1-propylbutyl)-, monohydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 860016-20-2 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(2,4-dibromophenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-22-4 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-21-3
CMF C25 H31 Br N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-24-6 CAPLUS
CN Methanamine, N-[4-(4-chloro-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-23-5
CMF C25 H31 Cl N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-25-7 CAPLUS
CN Methanamine, N-[4-[2-bromo-4-(1-methylethyl)phenyl]-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-26-8 CAPLUS
CN Methanamine, N-[4-[2-bromo-4-(trifluoromethyl)phenyl]-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-27-9 CAPLUS
CN Methanamine, N-[4-(2,4-dibromophenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-28-0 CAPLUS
CN Urea, [4-(4-bromo-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-

triazacyclopent[cd]inden-2(1H)-ylidene]- (9CI) (CA INDEX NAME)



RN 860016-29-1 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 860016-31-5 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-(1-ethylpropyl)-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-30-4
CMF C23 H27 Br N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-32-6 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-[(1R)-1-(methoxymethyl)propyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 860016-34-8 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-[(1R)-1-(methoxymethyl)propyl]-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-33-7
CMF C23 H27 Br N4 O

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-35-9 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-[(1S)-1-(methoxymethyl)propyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 860016-37-1 CAPLUS

CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-[(1S)-1-(methoxymethyl)propyl]-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-36-0
CMF C23 H27 Br N4 O

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-38-2 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-(1,3-dimethylbutyl)-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-40-6 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-(1,3-dimethylbutyl)-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-39-3
CMF C24 H29 Br N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-41-7 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-

dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-42-8 CAPLUS
CN Methanamine, N-[4-[2-bromo-4-(1-methylethyl)phenyl]-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:35:20 ON 02 AUG 2007)

FILE 'REGISTRY' ENTERED AT 10:37:42 ON 02 AUG 2007
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 42 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:38:23 ON 02 AUG 2007
L4 1 S L3 FULL

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.62	180.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -0.78 -0.78

FILE 'REGISTRY' ENTERED AT 10:41:25 ON 02 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 AUG 2007 HIGHEST RN 943895-11-2
DICTIONARY FILE UPDATES: 1 AUG 2007 HIGHEST RN 943895-11-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10584952closestpriorart.str

L5 STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5 STR



G1 H,Cb,Ak,OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,O,CN
G2 H,X,Cb,Ak,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO,O,S,N
G3 C,H,Cb,Ak
G4 C,H,O,Cb,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 10:41:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 146 TO 694
PROJECTED ANSWERS: 3 TO 163

L6 3 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 10:41:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 318 TO ITERATE

100.0% PROCESSED 318 ITERATIONS 45 ANSWERS
SEARCH TIME: 00.00.01

L7 45 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 352.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -0.78

FILE 'CAPLUS' ENTERED AT 10:41:57 ON 02 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Aug 2007 VOL 147 ISS 6
FILE LAST UPDATED: 1 Aug 2007 (20070801/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7 full
L8 2 L7

=> d ibib abs hitstr tot

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:638885 CAPLUS
DOCUMENT NUMBER: 143:153394
TITLE: Preparation of triaza-cyclopenta[cd]indene derivatives as CRF antagonists
INVENTOR(S): Nakazato, Atsuro; Okubo, Taketoshi; Nozawa, Dai; Tamita, Tomoko; Kennis, Ludo E. J.
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066178	A1	20050721	WO 2005-JP323	20050106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2552600	A1	20050721	CA 2005-2552600	20050106
EP 1704149	A1	20060927	EP 2005-703562	20050106
EP 1704149	B1	20070307		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1910187	A	20070207	CN 2005-80002037	20050106
AT 356129	T	20070315	AT 2005-703562	20050106
JP 2007517795	T	20070705	JP 2006-546615	20050106
US 2007060602	A1	20070315	US 2006-584952	20060913

PRIORITY APPLN. INFO.: JP 2004-1312 A 20040106
WO 2005-JP323 W 20050106

OTHER SOURCE(S): CASREACT 143:153394; MARPAT 143:153394
GI



I



Pr-i II

AB The title compds. I [R1, R2 = H, alkyl, cycloalkyl, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl, cycloalkyl, cycloalkylalkyl; R5 = H, alkyl, arylalkyl, carbamoyl; Ar = (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts] which have a high affinity for CRF receptors and are effective against diseases in which CRF is considered to be involved, were prepared E.g., a multi-step synthesis of II.HCl, starting from 8-(2-bromo-4-isopropylphenyl)-4-chloro-2-methylpyrrolo[1,2-a]pyrimidine-6-carbonitrile and 1-propylbutanamine, was given. Representative compds. I showed IC50 of ≤ 100 nM in CRF receptor binding test. An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, dermatitis, schizophrenia, pain, etc.

IT 860016-16-6P 860016-18-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triaza-cyclopenta[cd]indene derivs. as CRF antagonists)

RN 860016-16-6 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-18-8 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-[2-bromo-4-(1-methylethyl)phenyl]-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 860016-14-4P 860016-15-5P 860016-17-7P
860016-19-9P 860016-20-2P 860016-22-4P
860016-24-6P 860016-25-7P 860016-26-8P
860016-27-9P 860016-28-0P 860016-29-1P
860016-31-5P 860016-32-6P 860016-34-8P
860016-35-9P 860016-37-1P 860016-38-2P
860016-40-6P 860016-41-7P 860016-42-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triaza-cyclopenta[cd]indene derivs. as CRF antagonists)
RN 860016-14-4 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(2,4-dichlorophenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-15-5 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 6-methyl-1-(1-propylbutyl)-4-(2,4,6-trimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-17-7 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-chloro-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-19-9 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-[2-bromo-4-(trifluoromethyl)phenyl]-6-methyl-1-(1-propylbutyl)-, monohydrochloride

(9CI) (CA INDEX NAME)



● HCl

RN 860016-20-2 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(2,4-dibromophenyl)-6-methyl-1-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-22-4 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-21-3
CMF C25 H31 Br N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-24-6 CAPLUS
CN Methanamine, N-[4-(4-chloro-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-23-5
CMF C25 H31 Cl N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-25-7 CAPLUS
CN Methanamine, N-[4-[2-bromo-4-(1-methylethyl)phenyl]-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-26-8 CAPLUS
CN Methanamine, N-[4-[2-bromo-4-(trifluoromethyl)phenyl]-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-27-9 CAPLUS
CN Methanamine, N-[4-(2,4-dibromophenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-28-0 CAPLUS
CN Urea, [4-(4-bromo-2,6-dimethylphenyl)-6-methyl-1-(1-propylbutyl)-1,5,7b-

triazacyclopent[cd]inden-2(1H)-ylidene]- (9CI) (CA INDEX NAME)



RN 860016-29-1 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 860016-31-5 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-(1-ethylpropyl)-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-30-4
CMF C23 H27 Br N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-32-6 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-[(1R)-1-(methoxymethyl)propyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 860016-34-8 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-[(1R)-1-(methoxymethyl)propyl]-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-33-7
CMF C23 H27 Br N4 O

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-35-9 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-[(1S)-1-(methoxymethyl)propyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 860016-37-1 CAPLUS

CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-[(1S)-1-(methoxymethyl)propyl]-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-36-0
CMF C23 H27 Br N4 O

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-38-2 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-dimethylphenyl)-1-(1,3-dimethylbutyl)-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-40-6 CAPLUS
CN Methanamine, N-[4-(4-bromo-2,6-dimethylphenyl)-1-(1,3-dimethylbutyl)-6-methyl-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 860016-39-3
CMF C24 H29 Br N4



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 860016-41-7 CAPLUS
CN 1,5,7b-Triazacyclopent[cd]inden-2(1H)-imine, 4-(4-bromo-2,6-

dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 860016-42-8 CAPLUS
CN Methanamine, N-[4-[2-bromo-4-(1-methylethyl)phenyl]-6-methyl-1-(1-propylbutyl)-1,5,7b-triazacyclopent[cd]inden-2(1H)-ylidene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:216855 CAPLUS
DOCUMENT NUMBER: 112:216855
TITLE: Condensation reactions of tetracyanoethylene and its monoanion promoted by Lewis acids: synthesis and crystal, molecular, and electronic structure of a novel heterocycle, the 2,3,6,7-tetracyano-5-(tricyanoethenylimino)-3H-1,4,7b-triazabenzo[1,j]pentalenide ion
AUTHOR(S): Bonamico, Mario; Fares, Vincenzo; Flamini, Alberto; Imperatori, Patrizia
CORPORATE SOURCE: Ist. Teor. Strutt. Elettron. Comportamento Spettrochim. Composit. Coord., CNR, Rome, 00016, Italy
SOURCE: Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999) (1990), (1), 121-5
CODEN: JCPKBH; ISSN: 0300-9580

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:216855
GI



I

AB From the condensation reaction of tetracyanoethylene with its radical monoanion promoted by a Lewis acid [ZnCl2, AlCl3, or V(bpy)3, bpy = 2,2'-bipyridine], a novel heterocyclic carbanion I has been synthesized and characterized by X-ray, 13C NMR, IR, and UV spectroscopy and cyclic voltammetry measurements. The crystal and mol. structure of the title anion has been determined for the tetraphenylarsonium salt, and its electronic structure and the mechanism of formation are discussed.
IT 127123-06-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, crystal, and mol. structure of)
RN 127123-06-2 CAPLUS
CN Arsonium, tetraphenyl-, salt with 2-[(1,2,2-tricyanoethylidene)amino]-1,5,7b-triazacyclopent[cd]indene-3,4,6,7-tetracarbonitrile (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 127123-05-1
CMF C17 N11



CM 2

CRN 15912-80-8
CMF C24 H20 As

10/513699



```
=> d his

     (FILE 'HOME' ENTERED AT 10:35:20 ON 02 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 10:37:42 ON 02 AUG 2007
L1                STRUCTURE UPLOADED
L2              3 S L1
L3             42 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:38:23 ON 02 AUG 2007
L4              1 S L3 FULL

     FILE 'REGISTRY' ENTERED AT 10:41:25 ON 02 AUG 2007
L5                STRUCTURE UPLOADED
L6              3 S L5
L7             45 S L5 FULL

     FILE 'CAPLUS' ENTERED AT 10:41:57 ON 02 AUG 2007
L8              2 S L7 FULL
```